Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. It develops an antibody therapeutic product candidate inhibiting Chi3l1, a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1, and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome. The company is also developing three product candidates based on the whole proteome differential screening target discovery platform, including a malaria vaccine candidate against plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1) and/or against plasmodium falciparum Glutamic Acid Rich Protein (PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria product candidate targeting PfGARP. It has a license agreement with Elkurt, Inc. for FRG Antibodies, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.